M&A Deal Summary

Pasithea Acquires Alpha-5 Integrin

On June 22, 2022, Pasithea acquired life science company Alpha-5 Integrin for 4M USD

Acquisition Highlights
  • This is Pasithea’s 1st transaction in the Life Science sector.
  • This is Pasithea’s largest (disclosed) transaction.
  • This is Pasithea’s 1st transaction in the United States.
  • This is Pasithea’s 1st transaction in Virginia.

M&A Deal Summary
Date 2022-06-22
Target Alpha-5 Integrin
Sector Life Science
Buyer(s) Pasithea
Deal Type Add-on Acquisition
Deal Value 4M USD

Target

Alpha-5 Integrin

Charlottesville, Virginia, United States
Alpha-5 Integrin is a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for the treatment of amyotrophic lateral sclerosis and other neuroinflammatory disorders, such as Multiple Sclerosis. Alpha-5 Integrin is based in Charlottesville, Virginia.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Pasithea

Miami Beach, Florida, United States
Category Company
Founded 2020
Sector Life Science
Employees8
DESCRIPTION

Pasithea is a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders. Pasithea was founded in 2020 and is based in Miami Beach, Florida.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Add-on Acquisition) 1 of 2
State (Virginia) 1 of 1
Country (United States) 1 of 2
Year (2022) 1 of 2
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-10-12 AlloMek Therapeutics

Woodbridge, Connecticut, United States

AlloMek Therapeutics is a biotechnology company that provides CIP-137401, a potential macrocyclic mitogen-activated protein kinase kinase 1/2 (MEK) inhibitor for use in a range of CNS-related indications, including neurofibromatosis type 1 (NF1) and Noonan syndrome, as well as potential synergy with its existing multiple sclerosis (MS) development program. AlloMek Therapeutics is based in Woodbridge, Connecticut.

Buy -
Mergr

Product

Company

Legal